After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases

Allakos Inc ALLK has reported data from the EoDyssey Phase 3 study of lirentelimab in patients with eosinophilic duodenitis (EoD).
The trial met its histologic co-primary endpoint, but it did not achieve statistical significance on the patient-reported symptomatic co-primary endpoint in both the intent to treat (ITT) population and in a prespecified subpopulation.
Although positive numerical trends in the symptomatic endpoint were observed in this prespecified subpopulation, the results were not statistically significant.
Related: Allakos' Shares Nosedive After Lirentelimab Studies Fail To Achieve Statistical Significance On Symptomatic Endpoints.
The safety results of the trial were generally consistent with previously reported intravenous lirentelimab studies.
Mild to moderate infusion-related reactions occurred in 19.6% of lirentelimab-treated patients and 14.9% of placebo-treated patients.
Allakos is not planning to conduct additional studies in eosinophilic gastrointestinal diseases.
The company is focusing on developing lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Topline data from these studies are expected in 2H of 2023.
Additionally, Allakos is advancing AK006 into IND-enabling studies and plans to initiate a Phase 1 study in healthy volunteers in 1H of 2023.
Price Action: ALLK shares are down 17% at $3.84 during the premarket session on the last check Friday.